Open an account

Edesa Biotech

EDSA · NASDAQ

$2.77+$0.01 (+0.36%)TodayMarket closed ·
Prev close $2.76

About EDSA

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. The company is headquartered in Markham, Ontario and currently employs 17 full-time employees. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

Employees
17
Headquarters
Markham, Ontario
Listed
Aug 25, 2008
Sector
Health Care
Industry
Biotechnology
Website
edesabiotech.com

EDSA key statistics

Market cap
37.43M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
43.73K
Volume
18.56K
Open price
$2.71
High today
$2.92
Low today
$2.67
52 Week high
$20.32
52 Week low
$0.72

Edesa Biotech (EDSA) at a glance

Edesa Biotech (EDSA) last traded at $2.77, with a market cap of 37.43M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.67 and $2.92. The current price is 3.7% above the day's low and 5.1% below its high.

Volume so far is 18.56K shares, below the average of 43.73K shares a day.

Over the past year Edesa Biotech has ranged from $0.72 to $20.32, and now sits 10% of the way up that range.

Edesa Biotech met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY26 it reported -$0.60 per share against an estimate of -$0.5916.

The average analyst price target is $13.77, 397.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $13.77
Low
$5.05
Now
$2.77
High
$22.05

EDSA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 23.4% on average.

  1. Q4 FY24: reported -$0.29 per share against an estimate of -$0.5508
  2. Q1 FY25: reported -$0.48 per share against an estimate of -$0.3162
  3. Q2 FY25: reported -$0.30 per share against an estimate of -$0.3009
  4. Q3 FY25: reported -$0.25 per share against an estimate of -$0.2686
  5. Q4 FY25: reported -$0.32 per share against an estimate of -$0.272
  6. Q1 FY26: reported -$0.28 per share against an estimate of -$0.459
  7. Q2 FY26: reported -$0.49 per share against an estimate of -$0.2652
  8. Q3 FY26: reported -$0.60 per share against an estimate of -$0.5916

EDSA news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Akanksha Bakshi

    Edesa Biotech Stock Sinks After Fresh Capital Raise

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

  • Press releaseGlobe Newswire

    Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

Similar companies

Companies in the same industry as Edesa Biotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.